Asessment of Serum Procalcitonin Level in Patients with Chronic Obstructive Pulmonary Disease | ||
| Benha Journal of Applied Sciences | ||
| Article 40, Volume 6, Issue 6, December 2021, Pages 319-324 PDF (836.4 K) | ||
| Document Type: Original Research Papers | ||
| DOI: 10.21608/bjas.2021.214832 | ||
| Authors | ||
| S.A. Issa1; M.A. Elmahdy1; O.S. ElShimi2; M.E. ElNaggar1; M.M. Behairy1 | ||
| 1Chest Diseases, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||
| 2Clinical and Chemical Pathology, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt | ||
| Abstract | ||
| Chronic Obstructive Pulmonary Disease (COPD) is currently one of the leading causes of mortality in the globe, according to the World Health Organization. When COPD sufferers have an acute exacerbation, the infection-detecting hormone procalcitonin (PCT) may be administered (AECOPD). The development of COPD is linked to PCT and other viral inflammatory variables. The goal of this research was to determine the PCT level in patients with COPD. Methods: ELISA was used to monitor PCT levels throughout AECOPD and after the patient was stabilised. Study groups differed significantly in PCT results (P-value 0.001). Stable (2220.9 pg/ml) and exacerbation (2679 pg/ml) groups had higher levels, whereas the control group had considerably lower levels (1696.9 pg/ml). Compared to the control group (2220.9 pg/ml), it was considerably greater in the exacerbation group (2679 pg/ml). Conclusion: In patients with stable COPD and AECOPD, PCT has a negative relationship with severity. | ||
| Keywords | ||
| COPD; AECOPD; Procalcitonin | ||
|
Statistics Article View: 126 PDF Download: 378 |
||
